Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2022-03-02 00:00:00 ET · period of report 2022-02-28 · accession 0001209191-22-015157 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-02 | 2022-02-28 | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | A - Grant | $0.00 | +115.0K | 1.39M | +9% | $0 |
| DM | 2022-03-02 | 2022-03-01+ | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | S - Sale | $11.16 | -37.1K | 1.35M | -3% | -$413.9K |
| D | 2022-03-02 | 2022-02-28 | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | A - Grant | $0.00 | +275.0K | 275.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-28 | A | A | 115,000 | $0.00 | 1,389,862 | D | — | — | (F1) Represents shares of common stock underlying a time-based restricted stock unit award ("RSU"). The RSU vests in four (4) equal annual installments with the first annual vest taking place on March 1, 2023, provided the Reporting Person remains continuously employed by the Issuer through each annual vesting date. Vested shares will be delivered on the First Permissible Trading Day (as defined in the RSU Agreement) that occurs on or after the day when the RSUs vest. |
| 2 | Common | Common Stock | 2022-03-01 | S | D | 7,508 | $11.19 | 1,382,354 | D | — | — | |
| 3 | Common | Common Stock | 2022-03-02 | S | D | 29,588 | $11.15 | 1,352,766 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.08 to $11.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-02-28 | A | A | 275,000 | $0.00 | 275,000 | D | $11.36 · — to 2032-02-27 | 275,000 Common Stock | (F4) The option vests with respect to 25% of the underlying shares on February 28, 2023, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person provides continuous service to the Issuer through the applicable vesting date. |